

COLOGUARD® STOOL DNA SCREENING TEST COLORECTAL CANCER FACT SHEET

COLOGUARD FACTS



Cologuard has screened

**NEARLY 3
MILLION PEOPLE.**

Over half of those surveyed
were previously unscreened.^{v,vi}



Many national and regional payers have
begun paying for CRC screening at 45.
To date,

~74%

of Cologuard patients 45-49 have had
no out-of-pocket cost for screening.^{vii}



Nationwide,
more than

94% of all Cologuard patients
50+ have no out-of-pocket
costs for screening.^{viii}

COLORECTAL CANCER FACTS



51%

increase in colorectal cancer incidence among
adults younger than 50 from 1994-2014.ⁱ



Colorectal cancer is the second
leading cancer killer in the United
States and is expected to cause
more than

51,000

deaths in the U.S. in 2019.ⁱⁱⁱ



130,165

patients under age 50 were diagnosed
with colorectal cancer from 2004-2015.

Among these cases, more than half
(51.6%) were diagnosed with more
advanced stages of cancer (Stage III/IV)
versus 40% in those older than 50 years.ⁱⁱ



90%

of patients survive five years when colorectal
cancer is detected in early stages*.

14% of patients survive five years when the
disease is detected in late stage.^{iv}

ⁱWolf A, Fonham E, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. *CA Cancer J Clin.* 2018;68:250-281.

ⁱⁱVirostko J, Capasso A, Yankeelov TE, et al. Recent trends in the age at diagnosis of colorectal cancer in the US National Cancer Data Base, 2004-2015. *Cancer.* 2019;0:1-8.

ⁱⁱⁱSiegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin.* 2019;69:7-34.

^{iv}ACS. Cancer Facts & Figures 2019. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf>. Accessed August 22, 2019. *Stages I, IIa, IIb.

^vExact Sciences. Exact Sciences Presents New Data Reinforcing Performance of Cologuard®. Exact Sciences website. <https://investor.exactsciences.com/investor-relations/-press-releases/press-release-details/2019/Exact-Sciences-Presents-New-Data-Reinforcing-Performance-of-Cologuard/default.aspx>. Accessed July 31, 2019.

^{vi}Exact Sciences. Second-Quarter Revenue Increased 94 Percent to \$200 Million And Cologuard Test Volume Increased 93 Percent to 415,000. Exact Sciences website. <http://investor.exactsciences.com/-investor-relations/press-release-details/2019/Second-quarter-revenue-increased-94-percent-to-200-million-and-Cologuard-test-volume-increased-93-percent-to-415000/default.aspx/>. Accessed August 7, 2019.

^{vii}Exact Sciences estimate based on historical patient billing for tests resulting from orders placed by providers who made independent determinations of the medical necessity of same with patients in this age range following on-label promotional messaging.

^{viii}Exact Sciences estimate based on historical patient billing and impact of recently executed network agreements.